Johns Hopkins logo

Health Newsfeed

OVARIAN CANCER HELP

ANCHOR LEAD: CAN A MONOCLONAL ANTIBODY HELP WOMEN WITH OVARIAN CANCER?  ELIZABETH TRACEY REPORTS

Bevacizumab is a type of drug called a monoclonal antibody, which targets very specific receptors on cells and is known to be helpful in colon cancer.  Now research suggests a role for bevacizumab in ovarian cancer, but Deborah Armstrong, an ovarian cancer expert at Johns Hopkins, says patients who are likely to benefit may be limited.

ARMSTRONG:  I will say that I don’t know that this is or should be the standard of care for newly diagnosed ovarian cancer patients.  We don’t know if for example with bevacizumab if you get it with initial chemotherapy do you not get much benefit from it in the recurrent setting because we get a lot of benefit from it in the recurrent setting so if we’re deleting that benefit we’re probably removing a very effective and well-tolerated drug in the recurrent setting.  Potentially and most important would be is there a subgroup of patients, ten or twenty percent who get a lot of benefit from it.  If we could identify who benefits from it we can target bevacizumab with chemotherapy to those patients.   :32

Genetic assessments may help.  At Johns Hopkins, I’m Elizabeth Tracey.Miller describes population health as modestly profitable, and expects that trajectory to continue.  At Johns Hopkins, I’m Elizabeth Tracey.

 

 


Search Health NewsFeed

-----------------------------------------
Health NewsFeed Home | Hopkins Medicine Home